[go: up one dir, main page]

WO2012060790A3 - Water dispersible cefpodoxime proxetil formulations - Google Patents

Water dispersible cefpodoxime proxetil formulations Download PDF

Info

Publication number
WO2012060790A3
WO2012060790A3 PCT/TR2011/000255 TR2011000255W WO2012060790A3 WO 2012060790 A3 WO2012060790 A3 WO 2012060790A3 TR 2011000255 W TR2011000255 W TR 2011000255W WO 2012060790 A3 WO2012060790 A3 WO 2012060790A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
water dispersible
cefpodoxime proxetil
proxetil
cefpodoxime
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2011/000255
Other languages
French (fr)
Other versions
WO2012060790A2 (en
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2012060790A2 publication Critical patent/WO2012060790A2/en
Publication of WO2012060790A3 publication Critical patent/WO2012060790A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to pharmaceutical formulations comprising cefpodoxi proxetil.
PCT/TR2011/000255 2010-11-05 2011-11-03 Water dispersible cefpodoxime proxetil formulations Ceased WO2012060790A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/09168 2010-11-05
TR2010/09168A TR201009168A2 (en) 2010-11-05 2010-11-05 Water dispersible cefpodoxime proxetil formulations.

Publications (2)

Publication Number Publication Date
WO2012060790A2 WO2012060790A2 (en) 2012-05-10
WO2012060790A3 true WO2012060790A3 (en) 2012-09-20

Family

ID=45446166

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/TR2011/000251 Ceased WO2012060786A2 (en) 2010-11-05 2011-11-03 Cefpodoxime proxetil formulations comprising viscosity agent
PCT/TR2011/000255 Ceased WO2012060790A2 (en) 2010-11-05 2011-11-03 Water dispersible cefpodoxime proxetil formulations

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000251 Ceased WO2012060786A2 (en) 2010-11-05 2011-11-03 Cefpodoxime proxetil formulations comprising viscosity agent

Country Status (2)

Country Link
TR (1) TR201009168A2 (en)
WO (2) WO2012060786A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2833872A1 (en) * 2012-04-04 2015-02-11 Mahmut Bilgic Tablet formulations comprising cefpodoxime proxetil and clavulanic acid
CN103142506B (en) * 2013-04-03 2015-02-25 天津医药集团津康制药有限公司 Cefpodoxime proxetil granules and preparation method thereof
CN103230367B (en) * 2013-05-07 2014-11-12 山东罗欣药业集团股份有限公司 Cefpodoxime proxetil composition dry suspension and preparation method thereof
BR112017011591A2 (en) * 2014-12-01 2018-03-06 Sun Pharmaceutical Ind Ltd stable extended release composition, process for preparing the extended release composition

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067943A1 (en) * 2001-02-27 2002-09-06 Ranbaxy Laboratories Limited Oral pharmaceutical composition of cefpodoxime proxetil
WO2004004737A1 (en) * 2002-07-08 2004-01-15 Sankyo Company, Limited Cephalosporin preparation for oral use
WO2004006917A1 (en) * 2002-07-16 2004-01-22 Ranbaxy Laboratories Limited Dispersible tablets for oral administration
WO2007017895A2 (en) * 2005-05-05 2007-02-15 Lupin Limited Stabilized oral pharmaceutical compositions of cephalosporins
WO2011129792A1 (en) * 2010-04-13 2011-10-20 Mahmut Bilgic Water dispersible formulations comprising cefpodoxime proxetil

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486425A (en) 1980-09-30 1984-12-04 Sankyo Company Limited 7-[2-(2-Aminothiazol-4-yl)-2-(syn)-methoxyiminoacetamido]-3-methoxymethyl-3-cephem-4-carboxylates
JP4526247B2 (en) * 2002-07-08 2010-08-18 第一三共株式会社 Oral cephalosporins

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067943A1 (en) * 2001-02-27 2002-09-06 Ranbaxy Laboratories Limited Oral pharmaceutical composition of cefpodoxime proxetil
WO2004004737A1 (en) * 2002-07-08 2004-01-15 Sankyo Company, Limited Cephalosporin preparation for oral use
WO2004006917A1 (en) * 2002-07-16 2004-01-22 Ranbaxy Laboratories Limited Dispersible tablets for oral administration
WO2007017895A2 (en) * 2005-05-05 2007-02-15 Lupin Limited Stabilized oral pharmaceutical compositions of cephalosporins
WO2011129792A1 (en) * 2010-04-13 2011-10-20 Mahmut Bilgic Water dispersible formulations comprising cefpodoxime proxetil

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200416, Derwent World Patents Index; AN 2004-169094, XP002676813 *

Also Published As

Publication number Publication date
WO2012060790A2 (en) 2012-05-10
TR201009168A2 (en) 2012-05-21
WO2012060786A2 (en) 2012-05-10
WO2012060786A3 (en) 2012-07-26

Similar Documents

Publication Publication Date Title
IL277110A (en) Immunogenic anti-inflammatory compositions
WO2012042371A3 (en) Pharmaceutical composition
IL217828B (en) Crystalline molecular complex of zoledronic acid, lysine, and water, pharmaceutical compositions comprising the same and uses thereof
WO2011093824A3 (en) Effervescent formulations comprising cefaclor
PT2591091E (en) Method for the preparation of 1,3-propanediol from sucrose
WO2012064743A3 (en) Methods for improving heart function
WO2012060790A3 (en) Water dispersible cefpodoxime proxetil formulations
WO2011029536A3 (en) Use of cyclic keto-enols for combating plant pathogenic bacteria
WO2012026907A3 (en) Cefpodoxime proxetil formulations
WO2012080176A3 (en) Pharmaceutical compositions comprising alisporivir
ZA201300285B (en) Disconnector,particularly of the double-break double-movement type
WO2011097527A3 (en) Immunoprotection of therapeutic moieties using enhanced fc regions
IT1405996B1 (en) PROCEDURE FOR THE PREPARATION OF 2,5-DIAMINOTOLUOL
TR201002878A2 (en) Pharmaceutical compositions comprising cefpodoxime proxetil.
ITTO20110857A1 (en) PROCEDURE FOR THE PRODUCTION OF CYCLOHEXANONOSSIN.
EP2481097A4 (en) Photodiode of the type avalanche photodiode
IT1396373B1 (en) PROCEDURE FOR THE PREPARATION OF FESOTERODINE.
WO2012004073A3 (en) Use of beta-isophorone as solvent
WO2011152805A3 (en) Pharmaceutical composition comprising cefpodoxime proxetil and clavulanic acid
WO2013081563A3 (en) Stable voglibose tablet formulations
WO2012026908A3 (en) Cefpodoxime proxetil formulations comprising taste regulating agent
WO2011139250A3 (en) Water dispersible formulation comprising betahistine
IT1403154B1 (en) PROCEDURE FOR THE PREPARATION OF TRAMEZZINI DI TIPO SUSHI.
FR2941524B1 (en) The AZIMUT'HEURE
WO2011133385A3 (en) Novel ether-based compounds and their use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11805269

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11805269

Country of ref document: EP

Kind code of ref document: A2